Find Clinical Trials

Back My cancer has not gone away or has come back Just recurred

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

I want to enter information about my genetic testing (e.g, BRCA) and/or tumor testing results

I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target

Return only trials with results

Include all Phase 1 trials (i.e., dose-finding as well as expansion)

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

III

Platinum resistant ovarian cancer; 1-2 prior systemic therapies

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)

AZ, CA, CT, FL, GA, IL, IN, LA, MD, MA, NJ, NY, NC, OH, OR, PA, SD, TN, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Ovarian expansion for CDKN2A loss or mutation or ERBB2/ERBB3 amplification, mutation or over-expression, or high TMB or Advanced solid tumors with molecular alterations in AKT1, ATM, ATR, BRAF, BRCA1/2, CDK4/6 AMP, CDK12, CDKN2A, CDKN2B, CHEK2, CSF1R, FANCA, FGFR1/2/3/4, FLT3, KIT, MRE11A, MLH1, MSH2, MSH6, NBN, NTRK1/2/3 AMP, PALB2, PDGFR, PDGFRB, PMS2, POLD1, POLE, RAF-1, RAD51C, RET, TSC1/2, VEGFR, or with high MSI, high TMB, HRD+, or LOHhi

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

AL, AZ, CA, CT, FL, GA, HI, IL, IN, ME, MI, NE, NH, NM, NY, NC, ND, OH, OR, PA, SC, SD, TN, TX, UT, VA, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancers
Futibatinib	TAS-120, FGFR inhibitor TAS-120	FGFR1-4 inhibitor	Approved in Other Cancers
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Larotrectinib	Trk inhibitor LOXO-101, LOXO-101, Vitrakvi	pan-Trk kinase inhibitor	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Palbociclib	PD-0332991, PD0332991, Ibrance	CDK4/6 inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Pertuzumab	Perjeta, monoclonal antibody 2C4, rhuMAb2C4	HER2 dimerization inhibitor	Approved in Other Cancers
PHESGO	pertuzumab, trastuzumab, and hyaluronidase-zzxf	HER2 antagonist	Approved in Other Cancers
Regorafanib	BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga	Multi-targeted RTK inhibitor	Approved in Other Cancers
Sunitinib	Sutent, Sunitinib malate	VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit	Approved in Other Cancers
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate, Talzenna	PARP inhibitor	Approved in Other Cancers
Temsirolimus	Torisel, CCI-779	mTOR inhibitor	Approved in Other Cancers
Trastuzumab	Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody	HER2 antagonist	Approved in Other Cancers
Tucatinib	Irbinitinib, ONT-380	HER2 kinase inhibitor	Approved in Other Cancers

II

Advanced solid tumors with high MSI or high TMB

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)

CA, MA, NJ

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with HER2 amplification

A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

NJ, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Trastuzumab emtansine	trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine	ADC: anti-HER2 + microtubule destabilizer (DM1)	Approved in Other Cancers

II

Advanced solid tumors with IDH1 or IDH2 mutations

A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

CA, CT, FL, KS, MD, MA, MO, NH, NJ, NC, OH, OK, PA, TN, TX, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with CCND1/2/3 alterations or CDK4/6 amplifications

A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers

II

Advanced solid tumors

A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin		IL-2R agonist	Approved in Other Cancers
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers
Individual Patient TCR-Transduced PBL	autologous PBLs retrovirally-transduced with TCRs targeting neoantigens	Immune response against neoantigens	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with high MSI and with POLE, POLD, or BRCA1/2 mutations

A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability

NJ, NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Platinum sensitive ovarian cancer with BRCA1/2 mutations or HRD+ that must have benefited from and then progressed on prior PARP inhibitor

EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition

MA, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ceralasertib	ATR kinase inhibitor AZD6738, AZD6738	ATR kinase inhibitor	Clinical Trials
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with ARID1A or ATM alterations

Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ceralasertib	ATR kinase inhibitor AZD6738, AZD6738	ATR kinase inhibitor	Clinical Trials
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer

II

Recurrent ovarian cancer

A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling

CA, MN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Platinum sensitive ovarian cancer with first or second recurrence in peritoneal cavity

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Rintatolimod	Atvogen	TLR3 agonist and immune cell stimulator	Approved in Other Indications

II

Advanced solid tumors without BRCA1/2 mutations, with Homologous Recombination Repair gene mutations (e.g., ATM, PALB2, RAD51D) or HRD+

A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

MD, NE, NJ, NY, SD, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer

II

Recurrent ovarian cancer

Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®

OK, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Stenoparib	PARP/Tankyrase inhibitor 2X-121, E7449, 2X-121	PARP inhibitor	Clinical Trials

II

Advanced solid tumors

A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin		IL-2R agonist	Approved in Other Cancers
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Selected Young TIL		Immune response against tumor-associated antigens	Clinical Trials

II

Advanced solid tumors with moderate/high TMB

Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

KY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Tremelimumab	Ticilimumab, CP-675206, CP-675,206, CP-675, anti-CTLA4 human monoclonal antibody CP-675,206	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors (with tumor amenable to skin biopsy)

DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Capecitabine	Xeloda, CAPE	RNA processing and thymidylate synthase inhibitor	NCCN Guidelines for Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor	Approved in Ovarian Cancer
Liposomal doxorubicin	Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil	Topoisomerase II inhibitor	Approved in Ovarian Cancer
nab-Paclitaxel	Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007	Microtubule stabilizer/mitotic inhibitor	NCCN Guidelines for Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors

A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin		IL-2R agonist	Approved in Other Cancers
Autologous TILs		Immune response against tumor-associated antigens	Clinical Trials
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers

II

Advanced solid tumors that must have progressed on prior immunotherapy or cellular therapy (amenable to radiation therapy)

Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Radiation Therapy	Irradiation, Radiotherapy

II

Advanced solid tumors with brain metastases and NTRK, ROS1, CDK pathway or PI3K pathway alterations

Genomically-Guided Treatment Trial in Brain Metastases

AK, AZ, AR, CA, CO, CT, FL, GA, ID, IL, IA, KS, KY, LA, MA, MI, MN, MS, MO, MT, NE, NH, NJ, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancers
Paxalisib	GDC-0084, PI3K inhibitor GDC-0084, RG7666	PI3K/mTOR inhibitor	Clinical Trials

II

Platinum resistant or refractory ovarian cancer (at most 4 prior therapies for platinum resistant disease)

Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

MI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
ONC201	AKT/ERK inhibitor ONC201, TIC10	AKT and ERK kinase inhibitor	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with IDH1 mutations

Phase II Study of IDH1 Inhibitor Ivosidenib and Nivolumab in IDH1 Mutant Gliomas and Advanced Solid Tumors

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ivosidenib	AG-120	IDH1 inhibitor	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced HRD+ or LOH high solid tumors

A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer

AZ, CA, CO, GA, TX, UT, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with dMMR, high MSI or high TMB

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

CA, GA, IL, IA, KY, MI, NE, OR, TX, VA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
INBRX-106	INBRX-106: Hexavalent OX40 Agonist	Stimulates OX40 to increase T cell activation and immune response	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with FGFR alterations

A Phase II Study of Oral Infigratinib in Adult Patients With Advanced or Metastatic Solid Tumors With FGFR1-3 Gene Fusions or Other FGFR Genetic Alterations

OH

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Infigratinib	BGJ398, pan FGFR Kinase Inhibitor BGJ398	pan-FGFR kinase inhibitor	Approved in Other Cancers

II

Recurrent ovarian cancer (only detectable by rising CA125)

A Phase 2 Study of Zafirlukast for the Treatment of Tumor-marker Only Relapsed Ovarian Cancer

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Zafirlukast	Accolate	CYSLTR1 antagonist	Approved in Other Indications

II

Recurrent ovarian cancer (only detectable by rising CA125)

A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Carboplatin to Prevent Progression After Serologic Detection of Recurrent Ovarian Cancer

WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors (Phase II)

A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid Tumors

GA, LA, MI, NY, PA, SC, TN, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
NM21-1480		Stimulates 4-1BB (CD137) to increase T cell activation and immune response and blocks PD-L1 inhibition of T cells	Clinical Trials

II

Recurrent ovarian cancer with CCND1-3 or CDK4/6 amplifications or CDKN2A alterations

An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer

CA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Anastrozole	Arimidex	Aromatase inhibitor
Letrozole	Femara	Aromatase inhibitor	NCCN Guidelines for Ovarian Cancer

II

Advanced solid tumors with alterations in BRAF, RAF1, MEK1/2, ERK1/2 or NF1

A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.

IN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Temuterkib	LY3214996	ERK inhibitor	Clinical Trials

II

Advanced solid tumors with alterations in ARID1A, ATM, ATR, BAP1, BARD1, BRCA 1/2, BRIP1, CDK12, CHK1/2, FANCA/B/C/D2/E/F/G/I/J/L/M/N, IDH1/2, MRE11A, NBN, PALB2, RAD50/51/51B/51C/51D or RAD54L (only 1 prior platinum therapy; germ-line BRCA MUT patients must have progressed on prior PARP inhibitor)

A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

FL, MD, OK

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate, Talzenna	PARP inhibitor	Approved in Other Cancers

II

Recurrent ovarian cancer

Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3

MI, TX, UT, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nemvaleukin alfa	intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230	IL-2R/IL-15R beta and gamma agonist	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with alterations in AKT1/2/3, ALK, ERBB2, MDM2, NTRK1/2/3, PIK3CA (multiple mutations), ROS1 or with high TMB

Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

AL, AZ, CA, FL, GA, ID, MD, MI, MN, MT, NH, NJ, NM, NY, OH, OR, PA, TN, TX, VA, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Alectinib	AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802	ALK kinase inhibitor	Approved in Other Cancers
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancers
Idasanutlin	MDM2 antagonist RO5503781, RG7388, RO5503781	MDM2 antagonist	Clinical Trials
Inavolisib	RG6114, GDC-0077	PI3K alpha inhibitor	Clinical Trials
Ipatasertib	GDC-0068, Akt Inhibitor GDC-0068, RG7440	pan-AKT inhibitor	Clinical Trials
Trastuzumab emtansine	trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine	ADC: anti-HER2 + microtubule destabilizer (DM1)	Approved in Other Cancers

II

Recurrent low grade serous ovarian cancer

A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

AZ, CA, CT, FL, IL, MD, MN, MO, NV, NM, NY, OH, OK, OR, TN, TX, VA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Avutometinib	CH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766	RAF and MEK inhibitor	Clinical Trials
Defactinib	VS-6063, PF-04554878, PF-04554878	FAK inhibitor	Clinical Trials

II

Advanced solid tumors with leptomeningeal metastases

Phase II Trial of Pembrolizumab and Lenvatinib for Leptomeningeal Metastases

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Lenvatinib	MK-7902, Lenvima, ER-203492-00, E7080	Multi-targeted RTK inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors - intratumoral injection

A Phase 2 Trial of Non-ablative Cryosurgical Freezing and Multiplex Immunotherapy in Patients With Metastatic Solid Cancer

AZ

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Thermotherapy			Clinical Trials

II

Advanced solid tumors with c-Kit or PDGFRA mutations (except c-KIT V654A or T670I)

Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Avapritinib		PDGFRa and c-Kit inhibitor	Approved in Other Cancers

II

Platinum resistant ovarian cancer

Phase II Study With Safety Lead-In of Lenvatinib, Pembrolizumab, and Weekly Paclitaxel for Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer

OH

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Lenvatinib	MK-7902, Lenvima, ER-203492-00, E7080	Multi-targeted RTK inhibitor	Approved in Other Cancers
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Patients with progressive brain metastases with amplifications in CDK4, CDK6, CCND1, CCND2, CCND3 or CCNE1 or loss of CDKN2A

A Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK Pathway

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Palbociclib	PD-0332991, PD0332991, Ibrance	CDK4/6 inhibitor	Approved in Other Cancers

II

Advanced solid tumors

A Phase II Study Using the Administration of Autologous T-Cells Engineered Using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients With Metastatic Cancer

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Aldesleukin		IL-2R agonist	Approved in Other Cancers
Cyclophosphamide	Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida	DNA damaging agent	Approved in Ovarian Cancer
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor	Approved in Other Cancers
Sleeping Beauty Transposed PBL		Immune response against neoantigens	Clinical Trials

II

Advanced solid tumors with NTRK1-3 amplifications (at least 7 copies)

A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib (BAY2757556) in Subjects With NTRK Amplification Positive and Pan-TRK Positive Tumors

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Larotrectinib	Trk inhibitor LOXO-101, LOXO-101, Vitrakvi	pan-Trk kinase inhibitor	Approved in Other Cancers

II

Recurrent ovarian cancer with symptomatic ascites or pleural effusion

Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion

NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Pegcetacoplan	C3-targeted complement inhibitor APL-2, APL-2	Blocks the cleavage of C3	Approved in Other Indications
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Platinum resistant low-grade serous, low-grade endometrioid, clear cell, mucinous, undifferentiated, malignant Brenner tumors, small cell carcinoma of the ovary-hypercalcemic type or carcinosarcoma

A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

AZ, CA, MN, MO, NC, OK, OR, PA, TX, UT, VA, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Cobimetinib	XL518, GDC-0973, Cotellic	MEK1 inhibitor	Approved in Other Cancers
Giredestrant	GDC-9545, selective estrogen receptor downregulator GDC-9545	ER antagonist (SERD)	Clinical Trials
Inavolisib	RG6114, GDC-0077	PI3K alpha inhibitor	Clinical Trials
Ipatasertib	GDC-0068, Akt Inhibitor GDC-0068, RG7440	pan-AKT inhibitor	Clinical Trials
Letrozole	Femara	Aromatase inhibitor	NCCN Guidelines for Ovarian Cancer
Olaparib	Lynparza, AZD2281	PARP inhibitor	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Palbociclib	PD-0332991, PD0332991, Ibrance	CDK4/6 inhibitor	Approved in Other Cancers
Trastuzumab emtansine	trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine	ADC: anti-HER2 + microtubule destabilizer (DM1)	Approved in Other Cancers

II

Advanced solid tumors with ARID1A mutations

A Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Solid Tumors

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Advanced solid tumors with somatic mutations in ATM, BARD1, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCI/L, PALB2, PPP2R2A, RAD51B/C/D or RAD54L

A Phase II Trial of Niraparib and Dostarlimab Combination Therapy in Patients With Somatic Homologous Recombination Deficient Advanced or Metastatic Cancer

TN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Dostarlimab	TSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Niraparib	Zejula, MK4827	PARP inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors without TP53 mutations with MDM2 amplification (at least 12 copies)

A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors (MANTRA-2)

CA, FL, MA, MO, NY, NC, OH, SD, TN, TX, WA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Milademetan	DS-3032b, RAIN-32, Milademetan tosylate	MDM2 inhibitor	Clinical Trials

II

Advanced solid tumors with ARID1A mutations

A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

SC

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Tazemetostat	histone methyl transferase EZH2 inhibitor E7438, EPZ6438, E7438, Tazverik	EZH2 histone methyltransferase inhibitor	Approved in Other Cancers

II

Advanced solid tumors with brain metastases

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Lenvatinib	MK-7902, Lenvima, ER-203492-00, E7080	Multi-targeted RTK inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Recurrent ovarian cancer with prior PARP inhibitor (at most 4 prior chemotherapy regimens)

Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate, Talzenna	PARP inhibitor	Approved in Other Cancers
ZEN-3694	ZEN003694, BET bromodomain inhibitor ZEN-3694	BET inhibitor	Clinical Trials

II

Recurrent ER+ and/or PR+ ovarian cancer with alterations in PIK3CA, PIK3R1 or PTEN

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Copanlisib	BAY 80-6946, PI3K inhibitor BAY 80-6946	pan-PI3K inhibitor	Approved in Other Cancers
Fulvestrant	ZD9238, ICI 182,780, Faslodex	ER antagonist (SERD)	Approved in Other Cancers

II

Advanced solid tumors with ALK or ROS1 fusions, BRAF V600X, BRCA1/2, or gPALB2 alterations, or HER2+, Nectin-4+ or TROP2+, or IRS-H+ or Angio TRS-H+

Strata PATH™ (Precision Indications for Approved Therapies): A Study Evaluating the Clinical Activity and Safety of Approved Drugs Within Biomarker-Guided Patients With Solid Tumors

AR, DE, FL, IA, LA, OH, TN, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Axitinib	Inlyta, AG-013736	Multi-targeted RTK inhibitor
Binimetinib	MEK162, MEK inhibitor MEK162, ARRY-162, ARRY-438162, Mektovi	MEK inhibitor	Approved in Other Cancers
Encorafenib	Raf Kinase Inhibitor LGX818, LGX818	RAF inhibitor	Approved in Other Cancers
Enfortumab Vedotin		ADC: anti-Nectin-4 + microtubule destabilizer (MMAE)	Approved in Other Cancers
Lorlatinib	PF-06463922	ALK and ROS1 kinase inhibitor	Approved in Other Cancers
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Sacituzumab govitecan	Trodelvy, hrS7-SN38 antibody drug conjugate, anti-TROP-2 Antibody-Drug Conjugate IMMU-132	ADC: anti-TROP2 + topoisomerase I inhibitor (SN38)	Approved in Other Cancers
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate, Talzenna	PARP inhibitor	Approved in Other Cancers
Trastuzumab deruxtecan	T-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201a	ADC: anti-HER2 + topoisomerase I inhibitor (Dxd)	Approved in Other Cancers

II

Advanced solid tumors with TSC1/2 alterations

A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.

AL, AZ, CA, CO, CT, FL, GA, HI, IN, LA, MD, MA, MI, MO, NE, NV, NJ, NY, NC, OH, OK, PA, SC, SD, TN, TX, UT, VA, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
nab-Sirolimus	Nanoparticle Albumin-Bound Sirolimus, Nanoparticle Albumin-Bound Rapamycin, nab-rapamycin, ABI-009	mTOR inhibitor	Approved in Other Cancers

II

Recurrect low grade serous ovarian cancer

Efficacy of Oral Regorafenib Combined With Intra-muscular Injection of Fulvestrant in Patients With Recurrent Low-grade Serous Ovarian Cancer: A Phase II Single Arm Trial

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Fulvestrant	ZD9238, ICI 182,780, Faslodex	ER antagonist (SERD)	Approved in Other Cancers
Regorafanib	BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga	Multi-targeted RTK inhibitor	Approved in Other Cancers

II

Recurrent or persistent non-mucinous ovarian cancer with peritoneal disease (IP/IV)

Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Ovarian, or Other Gynecologic Primary Cancer

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Nilotinib	AMN 107, Tasigna	Bcr-abl, c-Kit, and PDGFR kinase inhibitor	Approved in Other Cancers
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Advanced solid tumors with loss of function PTCH1 mutations

A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

CA, FL, IL, LA, NV, NY, NC, OH, PA, TN, TX, VA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Taladegib	LY2940680, ENV-101	Smoothened antagonist	Clinical Trials

II

Ovarian cancer with brain metastases and alterations in ATM, ATR, BAP1, BARD1, BRCA1/2, BRIP1, MRE11A, NBN, PALB2, RAD50, RAD51B/C/D, RAD54B/L, XRCC2, or XRCC3 (with measurable disease in the CNS)

Genomically Guided Phase II Study to Evaluate the Clinical Benefit of Niraparib in Tumors Metastatic to the CNS

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Niraparib	Zejula, MK4827	PARP inhibitor	Approved in Ovarian Cancer

II

Recurrent serous, endometrioid or clear cell ovarian cancer

Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer

NY, TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
CDX-1140		Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response	Clinical Trials
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

II

Recurrent ovarian cancer

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)

OR

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Alectinib	AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802	ALK kinase inhibitor	Approved in Other Cancers
Alpelisib	PI3K inhibitor BYL719, BYL719, phosphoinositide 3-Kinase inhibitor BYL719, Piqray	PI3K alpha inhibitor	Approved in Other Cancers
Anastrozole	Arimidex	Aromatase inhibitor
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells	Approved in Other Cancers
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist	Approved in Ovarian Cancer
Capecitabine	Xeloda, CAPE	RNA processing and thymidylate synthase inhibitor	NCCN Guidelines for Ovarian Cancer
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Cobimetinib	XL518, GDC-0973, Cotellic	MEK1 inhibitor	Approved in Other Cancers
Entrectinib	RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek	ALK, TRK, ROS1 kinase inhibitor	Approved in Other Cancer